Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors

Pancreas

Volumn 42, Issue 3, 2013, Pages 411-421

  Gilbert, Judith A ^a   Adhikari, Laura J ^b   Lloyd, Ricardo V ^c   Halfdanarson, Thorvardur R ^d   Muders, Michael H ^e   Ames, Matthew M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Molecular analysis; Pancreatic endocrine tumors

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; AXITINIB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR A; PROTEIN P21; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CARCINOID; CELLS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; KIRSTEN SARCOMA ONCOVIRUS; MALE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR CELL;

BENZOQUINONES; CARCINOID TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG THERAPY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDAZOLES; LACTAMS, MACROCYCLIC; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZOLES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, SOMATOSTATIN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRIAZINES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84884211452     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31826cb243     Document Type: Article

References (44)

1. Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409-427.
2. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-1733.
3. Strosberg JR, Halfdanarson TR. Survival analyses of pancreatic neuroendocrine tumors: Contrasting institutional databases with population-based studies. J Clin Oncol. 2011;29(suppl 4):186.
4. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
5. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
6. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
7. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, et al. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer. 2010;17:623-636.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonYsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
9. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
10. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
11. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A southwest oncology group study. J Clin Oncol. 2005;23:6838-6845.
12. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol. 2005;6:279-286.
13. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007;25:3238-3245.
14. Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008;19:717-723.
15. Lievre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
16. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-515.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
18. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
19. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:57-61.
20. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonYsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
21. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in nonYsmall cell lung cancer. Clin Cancer Res. 2007;13:2890-2896.
22. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
23. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
24. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357-5364.
25. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-Methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338-345.
26. Adhikari LJ, Gilbert JA, Lloyd RV, et al. Biomarker expression in pancreatic endocrine tumors. Mod Pathol. 2011;24(suppl 1s):133A.
27. Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944-951.
28. Gilbert JA, Lloyd RV, Ames MM. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med. 2005;353:209-210.
29. Kaku M, Nishiyama T, Yagawa K, et al. Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma. Gann. 1980;71:596-601.
30. Cory AH, Owen TC, Barltrop JA, et al. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991;3:207-212.
31. Heitz PU, Komminoth P, Perren A, et al. Pancreatic endocrine tumours: Introduction. In: RA DeLellis, RV Lloyd, PU Heitz, C Eng, eds. Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004:177-182.
32. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
33. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptorYpositive nonYsmall-cell lung cancer patients. J Clin Oncol. 2005;23:5007-5018.
34. Roskoski R Jr. VEGF receptor protein-tyrosine kinases: Structure and regulation. Biochem Biophys Res Commun. 2008;375:287-291.
35. Kalthoff H, SchmiegelW, Roeder C, et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene. 1993;8:289-298.
36. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-1492.
37. Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005;18:1329-1335.
38. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
39. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
40. Ewald JA, Desotelle JA, Wilding G, et al. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102:1536-1546.
41. Furukawa M, Raffeld M, Mateo C, et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res. 2005;11:3233-3242.
42. Reidy DL, Hollywood E, Segal M, et al. A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R) in patients with metastatic well-differentiated neuroendocrine tumors (NETs). J Clin Oncol. 2010;28(suppl 15):4163.
43. Haluska P, Carboni JM, TenEyck C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor BMS-536924. Mol Cancer Ther. 2008;7:2589-2598.
44. Kulke MH, Lenz H-J, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-3410.